Format

Send to

Choose Destination
Clin Cancer Res. 2016 Feb 1;22(3):567-74. doi: 10.1158/1078-0432.CCR-15-0321. Epub 2015 Oct 7.

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.

Author information

1
GlaxoSmithKline, Collegeville, Pennsylvania.
2
GlaxoSmithKline, Collegeville, Pennsylvania. Robert.Gagnon@novartis.com.
3
Department of Medical Oncology, Melanoma Institute Australia and The University of Sydney, North Sydney, New South Wales, Australia.
4
Department of Dermatology, University Hospital Essen, Essen, Germany.
5
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
6
Department of Medical Oncology, Melanoma Institute Australia and The University of Sydney, North Sydney, New South Wales, Australia. Westmead Hospital, Crown Princess Mary Cancer Centre, Sydney, New South Wales, Australia.
7
Department of Dermatology, University Hospital Schleswig-Holstein, Germany.
8
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Abstract

PURPOSE:

Tumor-derived circulating cell-free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) trametinib were analyzed to determine the association between BRAF mutation status in cfDNA and tumor tissue, and the association of BRAF cfDNA mutation status with baseline factors and clinical outcome.

EXPERIMENTAL DESIGN:

Patients with BRAF V600 mutation-positive melanoma were enrolled in each study after central confirmation of BRAF status in tumor using a PCR-based assay. BRAF mutation status in cfDNA from patient plasma collected at baseline, 732 of 836 (88%) enrolled patients in total, was determined.

RESULTS:

BRAF mutations were detectable in cfDNA in 76% and 81% of patients with BRAF V600E/V600K-positive tumors, respectively. Patients negative for BRAF mutations in cfDNA had longer progression-free survival (PFS) and overall survival in each of the four studies, compared with patients with detectable cfDNA BRAF mutations. The presence of BRAF-mutant cfDNA was an independent prognostic factor for PFS after multivariate adjustment for baseline factors in three of four studies. Patients negative for BRAF mutation-positive cfDNA in plasma had higher response rates to dabrafenib and trametinib.

CONCLUSIONS:

BRAF mutations in cfDNA are detectable in >75% of late-stage melanoma patients with BRAF mutation-positive tumors. The lack of circulating, BRAF mutation-positive cfDNA is clinically significant for metastatic melanoma patients, and may be a prognostic marker for better disease outcome.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01153763 NCT01227889 NCT01245062 NCT01266967.

PMID:
26446943
DOI:
10.1158/1078-0432.CCR-15-0321
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center